List of Enstilar drug patents
Enstilar is owned by Leo Pharma As.
Enstilar contains Betamethasone Dipropionate; Calcipotriene.
Enstilar has a total of 10 drug patents out of which 0 drug patents have expired.
Enstilar was authorised for market use on 16 October, 2015.
Enstilar is available in aerosol, foam;topical dosage forms.
Enstilar can be used as plaque psoriasis; topical treatment of plaque psoriasis in patients 12 years and older, topical treatment of plaque psoriasis in patients 12 years and older.
The generics of Enstilar are possible to be released after 10 December, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119781 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10688108 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10660908 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US9566286 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10716799 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10682364 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10617698 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10130640 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
|
US9119781 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(8 years from now) | |
|
US10130640 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Jan 30, 2023 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 16 October, 2015
Treatment: Plaque psoriasis; Topical treatment of plaque psoriasis in patients 12 years and older
Dosage: AEROSOL, FOAM;TOPICAL
ENSTILAR family patents
12
United States
3
Japan
2
Israel
2
Korea, Republic of
2
Denmark
2
European Union
1
Australia
1
Croatia
1
Canada
1
New Zealand
1
Spain
1
Malaysia
1
Cyprus
1
Singapore
1
Portugal
1
Ukraine
1
Russia
1
Poland
1
Hong Kong
1
Slovenia
1
Mexico
1
Brazil
1
RS
1
South Africa
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic